Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis

A new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center...

Full description

Bibliographic Details
Main Authors:	Labrador-Horrillo, Moises, Martinez, Maria Angeles, Selva-O'Callaghan, Albert, Trallero-Araguas, Ernesto, Balada, Eva, Vilardell-Tarres, Miquel, Juárez, Cándido
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987881/

id	pubmed-3987881
recordtype	oai_dc
spelling	pubmed-39878812014-04-16 Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis Labrador-Horrillo, Moises Martinez, Maria Angeles Selva-O'Callaghan, Albert Trallero-Araguas, Ernesto Balada, Eva Vilardell-Tarres, Miquel Juárez, Cándido Research Article A new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center, and analyze the feasibility of detecting this autoantibody in patient sera using new assays with commercially available recombinant MDA5. The study included 117 white adult patients with DM, 15 (13%) of them classified as clinically amyopathic dermatomyositis (CADM). Clinical manifestations were analyzed, with special focus on interstitial lung disease and its severity. Determination of anti-MDA5 antibodies was performed by a new ELISA and immunoblot technique. In sera, from 14 (12%) DM patients (8 CADM), MDA5 was recognized by ELISA, and confirmed by immunoblot. Eight of the 14 anti-MDA5-positive patients (57.14%) presented rapidly-progressive interstitial lung disease (RP-ILD) versus 3 of 103 anti-MDA5-negative patients (2.91%) (P < 0.05; OR: 44.4, 95% CI 9.3–212). The cumulative survival rate was significantly lower in anti-MDA5-positive patients than in the remainder of the series (P < 0.05). Patients with anti-MDA5-associated ILD presented significantly lower 70-month cumulative survival than antisynthetase-associated ILD patients. Among the cutaneous manifestations, only panniculitis was significantly associated with the presence of anti-MDA5 antibodies (P < 0.05; OR: 3.85, 95% CI 1.11–13.27). These findings support the reliability of using commercially available recombinant MDA5 for detecting anti-MDA5 antibodies and confirm the association of these antibodies with RP-ILD in a large series of Mediterranean patients with DM. Hindawi Publishing Corporation 2014 2014-02-04 /pmc/articles/PMC3987881/ /pubmed/24741583 http://dx.doi.org/10.1155/2014/290797 Text en Copyright © 2014 Moises Labrador-Horrillo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Labrador-Horrillo, Moises Martinez, Maria Angeles Selva-O'Callaghan, Albert Trallero-Araguas, Ernesto Balada, Eva Vilardell-Tarres, Miquel Juárez, Cándido
spellingShingle	Labrador-Horrillo, Moises Martinez, Maria Angeles Selva-O'Callaghan, Albert Trallero-Araguas, Ernesto Balada, Eva Vilardell-Tarres, Miquel Juárez, Cándido Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
author_facet	Labrador-Horrillo, Moises Martinez, Maria Angeles Selva-O'Callaghan, Albert Trallero-Araguas, Ernesto Balada, Eva Vilardell-Tarres, Miquel Juárez, Cándido
author_sort	Labrador-Horrillo, Moises
title	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
title_short	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
title_full	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
title_fullStr	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
title_full_unstemmed	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
title_sort	anti-mda5 antibodies in a large mediterranean population of adults with dermatomyositis
description	A new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center, and analyze the feasibility of detecting this autoantibody in patient sera using new assays with commercially available recombinant MDA5. The study included 117 white adult patients with DM, 15 (13%) of them classified as clinically amyopathic dermatomyositis (CADM). Clinical manifestations were analyzed, with special focus on interstitial lung disease and its severity. Determination of anti-MDA5 antibodies was performed by a new ELISA and immunoblot technique. In sera, from 14 (12%) DM patients (8 CADM), MDA5 was recognized by ELISA, and confirmed by immunoblot. Eight of the 14 anti-MDA5-positive patients (57.14%) presented rapidly-progressive interstitial lung disease (RP-ILD) versus 3 of 103 anti-MDA5-negative patients (2.91%) (P < 0.05; OR: 44.4, 95% CI 9.3–212). The cumulative survival rate was significantly lower in anti-MDA5-positive patients than in the remainder of the series (P < 0.05). Patients with anti-MDA5-associated ILD presented significantly lower 70-month cumulative survival than antisynthetase-associated ILD patients. Among the cutaneous manifestations, only panniculitis was significantly associated with the presence of anti-MDA5 antibodies (P < 0.05; OR: 3.85, 95% CI 1.11–13.27). These findings support the reliability of using commercially available recombinant MDA5 for detecting anti-MDA5 antibodies and confirm the association of these antibodies with RP-ILD in a large series of Mediterranean patients with DM.
publisher	Hindawi Publishing Corporation
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987881/
_version_	1612078530986770432

Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis

Similar Items